# **Quarterly Industry Update**

As of July 31, 2013 Industry: Cardiovascular Device




### Industry Summary

Cogent Valuation identified publicly traded companies, IPOs, and recent M&A transactions within the Cardiovascular Device industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Since July 31, 2012, the median 52-week share price return of the Cardiovascular Device industry has increased by 24.6%. In the last quarter, the median price-to-earnings multiple increased from 20.4x to 25.7x. Revenue growth and profitability margins remain stable in this industry.

Comparable Public Company Key Statis	tics										
Median 52-Week Return	24.6%	Median EV/Revenue Multiple			ultiple	3.2x	M	25.7x			
Median 3-Year CAGR Return	13.4%	Median EV/EBITDA Multiple			tiple	11.7x	M	23.4x			
Comparable Public Company Market Pr	ice Returns (As o	of July 31, 20	)13)								
	YTD	3 Month	1 Year	2 Year	3 Year	5 Year	2012	2011	2010	2009	2008
Vascular Solutions Inc.	2.3%	1.6%	21.1%	11. <b>2</b> %	10.3%	15.6%	42.0%	-5.0%	39.7%	-7.0%	38.8%
BioTelemetry, Inc.	231.6%	159.8%	287.7%	22.5%	16.6%	-22.8%	-3.8%	-49.4%	-21.2%	-75.9%	N/A
ABIOMED, Inc.	86.6%	35.8%	11. <b>2</b> %	23.3%	31.3%	7.2%	-27.2%	<b>92.2</b> %	10.1%	-46.8%	5.7%
Edwards Lifesciences Corp.	-20.8%	11. <b>9</b> %	-29.5%	0.0%	7.3%	17. <b>9</b> %	27.5%	-12.5%	86.2%	58.1%	19.5%
Thoratec Corp.	-12.6%	-9.4%	-4.4%	-1.3%	-3.8%	11.8%	11.8%	18.5%	5.2%	-17.1%	78.6%
The Spectranetics Corporation	22.0%	-3.4%	52.7%	61.3%	51.7%	15.0%	104.6%	<b>39.9</b> %	-25.9%	166.7%	-83.0%
CryoLife Inc.	13.6%	18.0%	27.3%	10.8%	9.7%	-12.2%	29.8%	-11.4%	-15.6%	-33.9%	22.1%
Volcano Corporation	-15.4%	-1.6%	-24.5%	-20.3%	-3.3%	5.7%	-0.8%	-1 <b>2.9</b> %	57.1%	15. <b>9</b> %	19.9%
Boston Scientific Corporation	90.6%	45.8%	111. <b>2</b> %	23.5%	24.9%	-1.7%	7.3%	-29.5%	-15. <b>9</b> %	16.3%	-33.4%
Medtronic, Inc.	34.7%	18.3%	40.1%	23.8%	14.3%	0.9%	7.2%	3.1%	-15.7%	40.0%	-37.5%
CR Bard Inc.	17.2%	15.3%	17.8%	7.8%	13.4%	4.3%	14.3%	-6.8%	17.8%	-7.5%	-11.1%
St. Jude Medical Inc.	45.0%	27.1%	40.2%	6.1%	12.5%	2.4%	5.4%	-19.8%	1 <b>6.2</b> %	11. <b>6</b> %	-18.9%
Teleflex Incorporated	11.4%	1.7%	24.6%	14.8%	11. <b>9</b> %	5.3%	16.3%	1 <b>3.9</b> %	-0.1%	7.6%	-20.5%
Median of Industry Public Companies	17.2%	15.3%	24.6%	11.2%	12.5%	5.3%	11.8%	-6.8%	5.2%	7.6%	-2.7%

(Multiple year periods are calculated as the average annual return.)



#### Median Gross Profit, EBITDA, Net Income and Gross Cash Flow Margins 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Jan 2012 AP' 2012 APr 2013 1012012 000 2012 Jul 2011 Jul 2013 00,201 $2^{\circ}$ Jon Gross Profit EBITDA - - -Net Income - • • - Gross Cash Flow

#### Median Public Company Multiples of the Cardiovascular Device Industry

Date:	7/31/2011	10/31/2011	1/31/2012	4/30/2012	7/31/2012	10/31/2012	1/31/2013	4/30/2013	7/31/2013
EV/Revenues Multiple	2.9x	2.1x	2.0x	2.5x	2.6x	2.6x	3.0x	2.8x	3.2x
EV/EBITDA Multiple	10.3x	8.8x	9.1x	9.1x	9.1x	9.6x	11.7x	12.2x	11.7x
Price/Earnings Multiple	20.0x	16.3x	19.9x	21.9x	21.3x	24.4x	22.2x	20.4x	25.7x
EV/Gross Cash Flows Multiple	16.4x	13.7x	18.1x	20.3x	19.7x	20.8x	21.7x	18.9x	23.4x

This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for more information or questions in connection with this research report.

# **Quarterly Industry Update**

As of July 31, 2013 Industry: Cardiovascular Device




#### Industry Initial Public Offerings (dollars in millions, except share prices)

<u>Offer Date</u>	<u>Company Name</u>	Offer Price	<u>Shares Offered</u>	<u>Amount Raised</u>	<u>Total Assets</u>	<u>Debt</u>	LTM Revenues	<u>LTM EBITDA</u>	LTM Net Income	<u>LTM Cash Flows</u>
11/17/2011	Sphere Medical Holding PLC	\$1.46	15.1	\$22.1	\$19.4	\$0.0	\$0.0	(\$7.0)	(\$8.1)	(\$6.7)
4/18/2011	InspireMD, Inc.	\$1.50	7.0	\$10.4	\$12.7	\$1.5	\$4.5	(\$3.3)	N/A	(\$3.2)
2/10/2011	Kips Bay Medical, Inc.	\$8.00	2.1	\$16.5	\$6.2	\$0.0	\$0.2	(\$8.6)	N/A	(\$8.6)
3/18/2008	BioTelemetry, Inc.	\$18.00	3.4	\$81.0	\$103.0	\$2.8	\$64.9	\$4.8	N/A	\$8.5
6/14/2006	Volcano Corporation	\$8.00	6.8	\$54.4	\$62.0	\$31.1	\$95.3	(\$4.2)	(\$15.1)	\$0.6
12/7/2005	Lombard Medical Technologies PLC	\$2.76	16.5	\$45.4	\$11.8	\$7.4	\$0.1	\$0.0	N/A	\$0.5
8/5/2005	AtriCure, Inc.	\$12.00	4.0	\$48.0	\$12.5	\$0.0	\$25.5	(\$5.8)	(\$3.4)	(\$4.7)
8/11/2004	Stereotaxis Inc.	\$8.00	5.5	\$44.0	\$41.1	\$6.0	\$9.9	(\$29.8)	(\$50.8)	(\$29.2)
Median of All IPOs		nm	nm	\$44.7	\$16.1	\$2.1	\$7.2	(\$5.0)	(\$11.6)	(\$3.9)

### Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Size of Merger and Acquisition Transactions (dollars in millions)



**Disclosures and Limitations:** This research report is for informational and discussion purposes only. This report and any statements, figures, or opinions stated herein does not represent investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be Reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the contents of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the composite used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The contents of this report are not to be used as a basis for any work that Cogent Valuation may perform for you in the future. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE. This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for more information or questions in connection with this research report. Copyright © 2013 Cogent Valuation. All Rights Reserved.